Alzheimer's disease (AD) and Parkinson's disease (PD), the two most common neurodegenerative disorders in the elderly, have been hypothesized to share genetic determinants. Recently, Li et al.
INTRODUCTION
Alzheimer's disease (AD) and Parkinson's disease (PD) are the main causes of neurodegenerative disorders in the elderly. Both pathologies are multifactorial resulting from the complex interactions between environmental and genetics factors. AD shows strong evidence for genes contributing to disease susceptibility (between 60-80%) (1) whereas the genetic component of PD appears less important (between 20-30%) (2) . Interestingly, familial aggregation of these two disorders has been observed, suggesting a common genetic cause (3, 4) . This hypothesis has been reinforced by the observation that similar clinical and pathological characteristics can be found in AD and PD patients.
For instance, some PD patients develop dementia and some AD patients have Lewy bodies (5, 6) .
The characterisation of common causative genetic factors may be useful to better define physiopathological processes in both diseases. To date, several genes or loci of interest have been proposed. The ε4 allele of the apoliporotein E (APOE) gene is a major genetic risk factor in AD has been associated with an increased risk of developing PD in some studies. However, this observation was suspected to potentially result from an increase in dementia in PD cases bearing the ε4 allele (7) .
As yet unknown genes in common to AD and PD may lie on chromosomes 6 and 10. Loci in these chromosomes were reported to contain gene(s) that modify age at onset of AD and PD (8) . One gene on chromosome 10, the glutathione S-transferase, omega-1, received particular attention but contradictory findings in these diseases were reported (9) (10) (11) .
In contrast to the initial report (12), we did not observe an association of the rs760678 SNP with AD or PD risk in any of our populations. No deleterious impact of the rs760678 CC genotype was found on the risk of developing AD or PD (respectively, OR=0.92, p=0.26; OR=1.00; p=0.99, in the combined populations adjusted for center, Table 3 ). These results were furthermore similar when adjusted for age and gender for each population studied and independent of the APOE status in AD (data not shown). Finally, no association between the rs760678 SNP and age at onset of AD or PD was observed (data not shown).
We next combined Li et al's data with our own (Figure 1 ). The rs760678 CC genotype was still weakly associated with AD (OR=1.14, 95% CI [1.03-1.26 ], p=0.01) but not with PD (OR=1.10, 95% CI [0.97-1.27], p=0.13).
DISCUSSION
Based on analyses of 4,692 putative functional SNPs in 3,664 genes, Li et al. reported that the NEDD9 gene may be a new candidate genetic risk factor for AD and PD (12) . The CC genotype of the rs760678 SNP within this gene was associated with an increased risk of developing AD (N=3,521; OR=1.38 p=5.4x10 -6 ) and PD (N=1,464; OR=1.31 p=0.01). To further explore this observation, we assessed the association of this SNP with AD in three independent cases-controls populations (N=3,176) and with PD in two independent cases-controls populations (N=1,855). The combined cohorts had 99% and 82% power to detect OR of 1.38 and 1.31 for AD and PD respectively (assuming an α level of 0.05). Conversely to the initial report of Li et al., we were unable to detect an association even after combination of cohorts to generate an equivalent numbers of cases and controls in AD and PD studies (respectively, OR=0.92, p=0.26 and OR=1.00, p=0.99, in the combined populations).
Even if it has been argued that European population stratification does not represent a significant source of bias in epidemiological studies, recent SNP studies have highlighted significant patterns of structure within Europe along a north-south axis (15) . The analyses showed consistent clustering of the Mediterranean populations from other European populations which appear to be more similar (15) .
Since we mainly studied populations from the North of France and the UK, the genetic structures of the populations analyzed in ours and Li et al's reports are likely to be similar. However, we cannot exclude that a slight variation in LD could affect the levels of associations observed in the different independent populations. The discrepancy between ours and Li et al's findings maybe due to the presence of a different polymorphism being responsible for risk that is in linkage disequilibrium (LD) with the rs760678 variant. However, Li et al. have already explored this possibility to some degree by examining the LD profile in the HapMap data set (www.hapmap.org) upstream and down stream of rs760678, a region encompassing over a 500 kb region. Only seven SNPs, over 20.7 kb, share r 2 > 0.1 with rs760678. Supplementary analyses performed by Li et al. indicated that the rs760678 SNP alone explained the observed associations in their different populations (12) .
In this report, we restricted our analysis to the rs760678 SNPs because a repeat association with precisely the same variant in independent samples is the gold standard for the replication approach (16) . Our data do not support the claim that the rs760678 SNP in the NEDD9 gene is a genetic determinant of AD or PD. However, it is important to note that only SNPs referenced in the HapMap data set were analysed in the initial study. It is still possible that unknown SNPs potentially in LD with the rs760678 variant exist. Li et al. sequenced all the NEDD9 gene exons in 40 LOAD cases and only characterized one rare non-synonymous variant (12) . However, it is well established that cell-type specific regulatory transcriptional sequences may be located within introns (17,18) and in remote sequences. Only systematic and ambitious efforts in sequencing and genotyping (even rare variants) in combination with replication in large independent populations will help determine whether the NEDD9 gene is a genetic determinant of AD and PD or not.
MATERIALS AND METHODS

Subjects
The main characteristics of the different populations are described in Table 1 . Written informed consent for participation was given by all subjects, or a caregiver, legal guardian, or other proxy where patients had substantial cognitive impairment. The study protocols for all populations were reviewed and approved by the appropriate institutional review boards of each country.
Alzheimer case-control populations.
LILLE case-control study (19) . All samples were Caucasian from the north of France (AD cases n=770, controls n=659). Clinical diagnosis of probable AD was established according to the DSM-III-R and NINCDS-ADRDA criteria. Caucasian controls were defined as subjects without DMS-III-R dementia criteria and with integrity of their cognitive functions (MMS>25). Presence of family history of dementia was considered as a criterion of exclusion. Controls were recruited in retirement homes or from electoral rolls (altruistic volunteers).
ROUEN case-control study (19) . All subjects were Caucasian from the West of France. (AD cases n=739, controls n=691). Clinical diagnosis of probable AD was established according to the DSM-III-R and NINCDS-ADRDA criteria. Control subjects (mainly spouses of patients) were required to have a MMSE score above 28.
BIRMINGHAM case-control study (19) . All samples were Caucasian from Greater Birmingham (AD cases n=416, controls n=167). Clinical diagnosis of probable AD was established according to the DSM-III-R and NINCDS-ADRDA criteria. Control subjects were assessed using either DSM-III-R questionnaire or had a MMSE score above 28.
The APOE distribution of all the AD case-control study are indicated in Table S1 (see supplementary material).
Parkinson case-control populations.
AUSTARLIAN case-control study (20) . Prevalent PD cases (n=722) were recruited at the Movement Disorders clinic at Princess Alexandra Hospital. The diagnosis of probable or definite PD was made when the subject had a combination of three of the following features: resting tremor, rigidity, bradykinesia, postural instability; or two of these features with asymmetry in tremor, rigidity or bradykinesia. All subjects were examined by a Movement Disorders Neurologist (n=462 controls).
TERRE case-control study (20) . Participants were recruited through a French health insurance organisation, the Mutualité Sociale Agricole (MSA), which is responsible for the reimbursement of health related expenses to workers in the agricultural area (PD cases n=204, controls n=467). PD cases were recruited among subjects submitting their first application to benefit from the free health care coverage for PD. The diagnosis of PD was established using standard criteria after examination by a neurologist or, when such an examination was not possible, using information provided by the patient's neurologist. Controls were recruited among MSA affiliates. A maximum of three controls were matched with each case for age (±2 years), sex, and region of residency at the time of the study.
Genotyping
The rs760678 SNP was genotyped by Nla III digestion following PCR amplification using 5'-AACAGGGGCACCCTTATCAT-3' and 5'-GGGCGATTTTGTTGTATTCC-3' oligonucleotides.
Ninety individuals were randomly selected for direct sequencing and no discrepancies were observed (see supplementary material, Figure S1 ).
Statistical analysis
The SAS software release 8.02 was used for statistical analyses (SAS Institute, Cary, NC). To study the impact of the SNP (rs760678) on AD an PD, an univariate analysis was first performed using 
